Simvastatin is a type of drugs (white powder). It is used to lower cholesterol & triglycerides (types of fat) in the blood. Its brand name is Zocor. It is also obtainable as a generic drug. The costs of generic drugs are less than the brand-name version. It is made from fungus Aspergillusterreus. It belongs to a drug class known as HMG-CoA reductive inhibitors, also called statins. It is also used to lower the risk of heart attack, stroke, and other heart complications in people with coronary heart disease, diabetes, or other risk factors. It is used along with diet, exercise, and weight loss to decrease elevated lipid levels. It is taken by mouth.
Some of the common side effects are headaches, constipation, allergic reaction (itching/swelling & rash), stomach pain, weakness, upper respiratory infections, joint pain and nausea. Additionally, some serious side effects are liver problems, muscle spasms, jaundice (yellowing of the skin), extreme sensitivity to the sun, severe anemia, diarrhea, trouble breathing, rhabdomyolysis (muscle breakdown), and increased blood sugar levels.
According to study, “World Simvastatin Market Research Report 2024(covering USA, EU, China, South East Asia, Japan and etc)” the key companies operating in the world simvastatin market are Hisun, Eashu, Shandong Lukang, PKU Healthcare, Sinopharm Weiqida, North China Pharmaceutical Huasheng, Zhejiang Guobang, Qilu Antibiotics, Zhejiang Ruibang, Southwest Pharmaceutical, HuayiPharma, Hailing Chemipharma, ApeloaKangyu, Xinchang Pharmaceutical, Lianhuan, BjWinsunny, Jiangbei Pharmaceutical, Hisun Pharmaceutical, jingxin pharmaceutical, Dadi pharmaceutical.
Based on product type, simvastatin market is segmented into chemical synthesis and enzymatic synthesis. Based on dosage form, market is segmented into capsule, liquid and tablet. Based on strength of dosage, market is segmented into 5 mg, 10 mg, 20 mg, 40 mg and 80 mg. Based on mild interaction, market is segmented into aliskiren, ambrisentan, alvimopan, armodafinil, colestipol, coenzyme q10, fexofenadine, isradipine, fluvoxamine, orlistat, loratadine, sacubitril/valsartan, trazodone, telmisartan and valsartan. Based on application, market is segmented into obesity, cardiovascular disorders, inflammatory disorders and others. Based on sales channel, market is segmented into retail pharmacy, hospital pharmacy and online pharmacy. In addition, based on end-user, market is segmented into hospitals and clinics.
The simvastatin market is driven byrise in prevalence of cholesterol, followed by change in lifestyle, increase in health awareness among people, rise in technological advancements, increase in biotechnology & pharmaceutical industries for research & development (R&D), presence of government initiatives, rapid urbanization &increase in disposable income and rise in patients with cardiovascular diseases, obesity, and diabetes. However, degrading socioeconomic conditions and high cost of medicines may impact the market.
Based on geography, EU and USA countries hold major share in simvastatin market owing to rise in demand for effective treatment of low density lipoproteins (LDL) cholesterol, modern healthcare amenities and increase in healthcare expenditure in the regions. Japan and China countries are expected to witness higher growth rate due to increase in patient population, surge in cholesterol related healthcare campaign and rise in innovative products over the forecast period. It is estimated that the market will be reached at rapid pace on account of rise in health awareness among patients and increase in cardiovascular diseases during the forecast period.
For More Information, click on the link below:-
Ankur Gupta, Head Marketing & Communications